BACKGROUND AND PURPOSE Patients with renal impairment (RI) have an increased risk of both thrombotic and hemorrhagic events. We aimed to clarify whether RI increases the risk of intracerebral hemorrhage (ICH) after intravenous thrombolysis with recombinant tissue plasminogen activator. METHODS Patients who received intravenous thrombolysis with recombinant tissue plasminogen activator within ...

The development of additional effective therapies for acute ischemic stroke remains a challenging but critical endeavor. Intravenous recombinant tissue plasminogen activator (rtPA) initiated within 3 hours of stroke onset remains the only approved and validated therapy for acute ischemic stroke, and regulatory approval has expanded recently. Many other therapies have been evaluated, and these t...

As cardiological trials become globalized, significant geographic variations in clinical outcomes become apparent, as was pointed out by the InTIME-II study and the accompanying editorial by van de Werf. The latter enumerated several factors among which ethnicity was thought to be an important demographic determinant of outcome. Van de Werf put forth the conjecture that ‘lower doses of fibrin s...

The development of additional effective therapies for acute ischemic stroke remains a challenging but critical endeavor. Intravenous recombinant tissue plasminogen activator (rtPA) initiated within 3 hours of stroke onset remains the only approved and validated therapy for acute ischemic stroke, and regulatory approval has expanded recently. Many other therapies have been evaluated, and these t...

BACKGROUND AND PURPOSE Thrombolytic treatment of stroke carries the risk of hemorrhagic transformation. Therefore, the potential of MRI for prediction of recombinant tissue plasminogen activator (rtPA)-induced bleeding is explored to identify patients in whom rtPA treatment may provoke such complications. METHODS Spontaneously hypertensive rats (SHR) (n=9) were submitted to middle cerebral ar...